• PDF / 169,725 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 11 Downloads / 179 Views

DOWNLOAD

REPORT

---

1 S

Ixekizumab/secukinumab Crohn’s disease and ulcerative colitis: 5 case reports

In a retrospective cohort study of patients with psoriasis who were identified by using electronic health records data, five women aged approximately 45–69 years [exact ages at onset not stated] were described, who developed ulcerative colitis or Crohn’s disease during treatment with secukinumab or ixekizumab for psoriasis [routes, dosages, durations of treatments to reactions onsets and outcomes not stated]. The woman, who had psoriasis, started receiving secukinumab in her late 40s. She had a history of hidradenitis suppurativa, rheumatoid arthritis and psoriatic arthritis. She was also receiving azathioprine and etanercept. During the treatment she developed secukinumab-induced Crohn’s disease. The woman, who had psoriasis, started receiving secukinumab in her late 50s. She had a history of psoriatic arthritis. She was also receiving ustekinumab. During the treatment she developed secukinumab-induced ulcerative colitis. The woman, who had psoriasis, started receiving ixekizumab in her early 60s. She had a history of psoriatic arthritis. During the treatment she developed ixekizumab-induced ulcerative colitis. The woman, who had psoriasis, started receiving secukinumab in her late 60s. She had a history of psoriatic arthritis and was receiving unspecified non steroidal anti-inflammatory drugs. During the treatment she developed secukinumab-induced Crohn’s disease. The woman, who had psoriasis, started receiving secukinumab in her late 60s. She had a history of psoriatic arthritis and was receiving unspecified non steroidal anti-inflammatory drugs. During the treatment she developed secukinumab-induced Crohn’s disease. Wright S, et al. Real-world risk of new-onset inflammatory bowel disease among patients with psoriasis exposed to interleukin 17 inhibitors. Journal of the American Academy of Dermatology 83: 382-387, No. 2, Aug 2020. Available from: URL: http://doi.org/10.1016/j.jaad.2020.04.010

0114-9954/20/1820-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

803499622

Reactions 5 Sep 2020 No. 1820